Amarin Corp Plc (AMRN)

[sts66]

there were two primary criteria the DMC had to conclude favorably on if they wanted to decide that REDUCE-IT was unethical to continue to completion based on overwhelming efficacy.

Well hey now - "unethical to continue" is way different than meeting a high bar for efficacy IMO - if that's true, there was no "if PE RRR is XX% you can halt at 80% IA" rule in place.

Regarding other potential applications for Vascepa, we have done feasibility work showing that it is possible to combine Vascepa with statin therapy which work is on hold until after the REDUCE-IT results.

That's AMR-102, they mentioned they had stopped all work due to ANCHOR debacle (uncertainty about FDA) during the Q2 CC.

We have also provided Vascepa to third-parties who are independently researching some potential other applications for Vascepa all of which are in their early stages.

I *think* we may have known this, but I don't remember what clinics or universities they are providing V to or for what purpose - Brighan and Women's comes to mind for a specific subgroup - also don't think these kinds of non-company funded trials need to be on clinicaltrials.gov.